March 21, 2018 / 9:30 PM / 4 months ago

BRIEF-Regeneron, Alnylam Pharmaceuticals Announce Collaboration To Discover New Treatments For Nonalcoholic Steatohepatitis

March 21 (Reuters) - Alnylam Pharmaceuticals Inc:

* REGENERON AND ALNYLAM PHARMACEUTICALS ANNOUNCE COLLABORATION TO DISCOVER NEW TREATMENTS FOR NONALCOHOLIC STEATOHEPATITIS (NASH)

* ALNYLAM PHARMACEUTICALS INC - REGENERON WILL CONTRIBUTE RESEARCH ON HEPATOCYTE-EXPRESSED, GENETICALLY-VALIDATED HSD17B13 TARGET

* ALNYLAM PHARMACEUTICALS INC - ALNYLAM WILL LEVERAGE ITS RNAI THERAPEUTICS PLATFORM TO IDENTIFY COMPOUNDS DIRECTED TO TARGET

* ALNYLAM - CO, REGENERON INTEND TO ENTER SEPARATE, 50-50 COLLABORATION TO FURTHER RESEARCH, CO-DEVELOP ANY THERAPEUTIC PRODUCT COMING FROM DISCOVERY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below